Non Small Cell Lung Cancer Stage III Clinical Trial
Official title:
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
This is an observational, prospective, multicentre and nationwide study. The study enroll resectable stage IIIA non-small cell lung cancer patients that are going to receive neoadjuvant treatment in real world. The primary objective of this study is evaluating whether there is a significant association between ctDNA clearance (no detection of ctDNA) after neoadjuvant treatment and before surgery and progression free survival.
This is an observational, multicenter, one-arm, non-comparative, prospective study that will not under any circumstances interfere in the physician's normal clinical practice. Being limited to the collection of blood samples at five times and patient data, it does not entail any diagnostic or therapeutic procedure outside of normal clinical practice. Approximately 100 resectable stage IIIA non-small cell lung cancer patients that are going to receive neoadjuvant treatment in real world will be recruited for this study in Spain. With this figure, it can be estimated whether ctDNA, both baseline and its negativization, has a role as a prognostic marker in the evolution of these patients in real-life conditions. The primary objective of this study is evaluate whether there is a significant association between ctDNA clearance (no detection of ctDNA) after neoadjuvant treatment and before surgery and progression free survival. The study is planned with the recruitment of patients over a year to a follow-up of 36 months post-surgery. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02247713 -
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
|
N/A | |
| Recruiting |
NCT04711330 -
Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
|
||
| Not yet recruiting |
NCT04465968 -
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
|
Phase 3 | |
| Completed |
NCT03845270 -
Her2-positive Lung Cancer Treated With Dedicated Drug
|
Phase 2 | |
| Active, not recruiting |
NCT04392505 -
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
|
Phase 2 | |
| Completed |
NCT04577638 -
Accelerated Radio-Immunotherapy for Lung Cancer
|
Phase 2 | |
| Terminated |
NCT04289259 -
Tumor Mutational Burden in Lung Cancer Patients
|
||
| Recruiting |
NCT04672759 -
A Real-world Study of Durvalumab for Lung Cancer in China
|
||
| Completed |
NCT03569072 -
High Intensity Functional Image Guided Vmat Lung Evasion
|
N/A | |
| Recruiting |
NCT02622581 -
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
|
||
| Completed |
NCT03055715 -
Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC
|